Skip to main content

Table 1 Characteristics of the study population

From: Impact of corticosteroids and immunosuppressive therapies on symptomatic SARS-CoV-2 infection in a large cohort of patients with chronic inflammatory arthritis

 

Total

n = 2.050

RA

n = 1.228

UA

n = 127

PsA

n = 398

SpA

n = 297

Age, mean (SD), years

57.8 (14.9)

61.4 (14.5)

57.8 (17.1)

54.6 (12.6)

47.5 (12.7)

Female gender, n (%)

1.354 (66)

943 (76.8)

91 (71.7)

196 (49.2)

124 (41.8)

Current smokers, n (%)

276 (16.5)

147 (14.6)

23 (19.3)

57 (18.3)

49 (20.7)

BMI, mean (SD)

25.2 (5.1)

25.0 (5.1)

25.7 (4.8)

26 (5.9)

24.8 (4.1)

 Overweight, n (%)

525 (32.5)

304 (31)

39 (31.5)

102 (35.3)

80 (36)

 Obese, n (%)

233 (14.4)

130 (13.3)

25 (20.2)

58 (20.1)

20 (9)

Hypertension, n (%)

643 (32.5)

430 (36.2)

45 (35.7)

113 (29.8)

55 (19.2)

Diabetes, n (%)

158 (8)

109 (9.2)

6 (4.8)

31 (8.2)

12 (4.2)

Disease duration, median (IQR), years

10 (5–16)

10 (5.9–18)

3.8 (2–6)

10 (5–15)

10 (5–16)

Use of PDN, n (%)

641 (31.3)

511 (41.6)

29 (22.8)

70 (17.6)

31 (10.4)

PDN dose, mean (SD), mg/day

4.3 (3.3)

4.3 (3.1)

3.3 (2.2)

4.9 (4.2)

4.7 (4.5)

 < 2.5 mg/day, n (%)

57 (8.9)

45 (8.8)

5 (17.2)

5 (7.1)

2 (6.5)

 2.5–5 mg/day, n (%)

522 (81.4)

417 (81.6)

23 (79.4)

55 (78.6)

27 (87)

 > 5 mg/day, n (%)

62 (9.7)

49 (9.6)

1 (3.4)

10 (14.3)

2 (6.5)

Use of HCQ, n (%)

382 (18.6)

284 (23.1)

72 (56.7)

21 (5.3)

5 (1.7)

Use of csDMARDs, n (%)

1.048 (51.2)

733 (59.7)

24 (19)

217 (54.5)

74 (24.9)

 MTX, n (%)

889 (43.4)

649 (52.9)

17 (13.5)

175 (44)

48 (16.2)

 SSZ, n (%)

98 (4.8)

32 (2.6)

7 (5.6)

35 (8.8)

24 (8.1)

 LFN, n (%)

53 (2.6)

45 (3.7)

0 (0)

6 (1.5)

2 (0.7)

 Others, n (%)

27 (1.3)

16 (1.3)

0 (0)

9 (2.3)

2 (0.7]

Use of b/tsDMARDs, n (%)

1.278 (62.3)

735 (59.9)

0 (0)

291 (73.1)

252 (84.8)

 TNF antagonists

743 (36.2)

339 (27.6)

 

186 (46.7)

218 (73.4)

 IL6-R antagonists

136 (6.6)

136 (11.1)

 

0 (0)

0 (0)

 IL17-IL23 antagonists

95 (4.6)

1 (0.08)

 

63 (15.8)

31 (10.4)

 CTLA4 Ig

146 (7.1)

145 (11.8)

 

1 (0.3)

0 (0)

 Rituximab

14 (0.7)

14 (1.1)

 

0 (0)

0 (0)

 JAK inhibitors

93 (4.5)

91 (7.4)

 

1 (0.3)

1 (0.3)

 IL1-R antagonists

8 (0.4)

8 (0.7)

 

0 (0)

0 (0)

 Others

43 (2.1)

1 (0.08)

 

40 (10.1)

2 (0.7)

  1. RA rheumatoid arthritis, UA undifferentiated arthritis, PsA psoriatic arthritis, SpA spondyloarthritis, BMI body mass index, PDN prednisone, HCQ hydroxychloroquine, csDMARDs conventional synthetic disease-modifying anti-rheumatic drugs, MTX methotrexate, SSZ sulfasalazine, LFN leflunomide, b/tsDMARDs biological/targeted synthetic disease-modifying anti-rheumatic drugs, TNF tumor necrosis factor, IL interleukin, R receptor, CTLA4 cytotoxic T lymphocyte antigen 4, JAK Janus kinase